Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Real World Evidence

BBCR Company News

Inventor of the PCR, Kary Mullis, Dies

August 15th, 2019 | Real World Evidence

Longer Stretch To The Finish Line for CNS Diseases

August 7th, 2019 | Real World Evidence

Cost vs. Value: Can We Have Both?

August 1st, 2019 | Real World Evidence

Could Seamless Adaptive Designs Advance Rare Disease Clinical Trial Design?

July 24th, 2019 | Real World Evidence

Gene Therapy for Rare Disorders Europe 2019 – October 15th – 17th, London

July 15th, 2019 | Real World Evidence

BBCR is Hiring! Boston Biotech Clinical Research is looking for a Full Time Associate Clinical Scientist to join our team!

June 21st, 2019 | Real World Evidence

SCIO Helps Early Stage Biotech Company Evaluation

January 24th, 2019 | Real World Evidence

A success story by BBCR Consulting: Candida Fratazzi MD was CMO at Ichorion Therapeutics in 2018

December 17th, 2018 | Real World Evidence

Welcome to BBCR’s New Website!

December 7th, 2018 | Real World Evidence
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • In the areas of rare disease, BBCR’s mission is to deliver cost-effective clinical plans and regulatory strategies for cell and gene therapy programs. Learn more at bbcrconsulting.com.
  • Building a Stronger Path to Market Through Early Clinical Research Strategy
  • Why Early Clinical Research Strategy Is Critical to Successful Drug Development
  • Why Rare Disease Drug Development Requires a Different Clinical Strategy
  • Why do orphan drug launches require specialized strategic planning?

RSS feed: Nasdaq Globe Newswire Nasdaq Globe Newswire

  • Forge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicines September 22, 2026
  • Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib September 22, 2026
  • Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing September 22, 2026
  • Emerging Trends & Investment Opportunities in the Mass Spectrometry Market 2026-2035 September 22, 2026
PRIVACY POLICY
  • LinkedIn

©2026 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs